norbuprenorphine has been researched along with Drug Withdrawal Symptoms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alund, AW; Brents, LK; Cabanlong, CV; Caperton, CO; Fantegrossi, WE; Griffin, BA; Martins, BS; Moran, JH; Owens, SM; Patton, AL; Russell, LN; Urquhart, KR; Wilson, CD; Zita, MD | 1 |
| Adeniji, A; Elgadi, M; Huang, F; Joseph, D; Riesenberg, RR; Schobelock, MJ; Vince, BD; Webster, LR | 1 |
| Carroll, FI; Damaj, MI; Jackson, KJ; Negus, SS | 1 |
| Cone, EJ; Fudala, PJ; Johnson, RE; Kuhlman, JJ; Levine, B | 1 |
2 trial(s) available for norbuprenorphine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.
Topics: Administration, Oral; Adult; Aminoisobutyric Acids; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Drug Interactions; Female; Humans; Leucine; Male; Methadone; Middle Aged; Oligopeptides; Proline; Quinolines; Substance Withdrawal Syndrome; Substance-Related Disorders; Thiazoles; Young Adult | 2015 |
Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine.
Topics: Administration, Sublingual; Buprenorphine; Heroin Dependence; Humans; Male; Narcotic Antagonists; Substance Withdrawal Syndrome; Time Factors | 1998 |
2 other study(ies) available for norbuprenorphine and Drug Withdrawal Symptoms
| Article | Year |
|---|---|
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.
Topics: Animals; Animals, Newborn; Buprenorphine; Female; Fetus; Opioid-Related Disorders; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Risk; Substance Withdrawal Syndrome | 2019 |
Effect of the selective kappa-opioid receptor antagonist JDTic on nicotine antinociception, reward, and withdrawal in the mouse.
Topics: Analgesics; Animals; Anxiety; Buprenorphine; Dose-Response Relationship, Drug; Hyperalgesia; Hypothermia; Male; Mice; Morphine; Nicotine; Piperidines; Receptors, Opioid, kappa; Reward; Substance Withdrawal Syndrome; Tetrahydroisoquinolines | 2010 |